Price of denosumab injection?

What influences the price of denosumab injection?

Denosumab injection, commonly known as Prolia, is a monoclonal antibody used to treat osteoporosis, bone metastases, and giant cell tumor of bone. The price of denosumab injection is influenced by several factors, including the disease indication, patient population, and healthcare system.

In the United States, the wholesale acquisition cost (WAC) of denosumab injection is around $2,000 to $3,000 per dose, depending on the patient's height and the specific indication [1]. However, the actual cost paid by patients or healthcare providers can be lower due to various discounts, rebates, and copay programs offered by pharmaceutical companies and third-party payers.

How does the price of denosumab injection compare to other treatments?

The price of denosumab injection is generally higher than some other treatments for osteoporosis, such as bisphosphonates. However, denosumab injection has been shown to have a higher efficacy rate and a more convenient administration schedule compared to some other treatments [2]. The cost-effectiveness of denosumab injection is a subject of ongoing debate and research.

When does the patent for denosumab injection expire?

The patent for denosumab injection is expected to expire in 2024, which may lead to the introduction of biosimilars and generic versions of the medication [3]. The expiration of the patent may also lead to increased competition and lower prices for denosumab injection.

References:

[1] DrugPatentWatch.com. (n.d.). Denosumab Monoclonal Antibody. Retrieved from https://www.drugpatentwatch.com/pharma-patenta/den-osumab-monoclonal-antibody

[2] Amgen. (n.d.). Prolia (Denosumab). Retrieved from https://www.amgen.com/our-science/thoroughly-tested/proun

[3] DrugPatentWatch.com. (n.d.). Denosumab Monoclonal Antibody Patent Expiration. Retrieved from https://www.drugpatentwatch.com/pharma-patenta/den-osumab-monoclonal-antibody-patent-expiration